NCIt definition : An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential
anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration,
baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition
of the JAK-signal transducers and activators of transcription (STAT) signaling pathway.
This decreases the production of inflammatory cytokines and may prevent an inflammatory
response. In addition, baricitinib may induce apoptosis and reduce proliferation of
JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine
signaling, inflammation, immune function and hematopoiesis; they are also upregulated
and/or mutated in various tumor cell types.;
UNII : ISP4442I3Y;
InChIKey : XUZMWHLSFXCVMG-UHFFFAOYSA-N;
CAS number : 1187594-09-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1187594-09-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Olumiant;
Molecule name : INCB028050; LY3009104; LY 3009104; INCB 028050;